Literature DB >> 6445041

A new immunodeficiency disorder in humans involving NK cells.

J C Roder, T Haliotis, M Klein, S Korec, J R Jett, J Ortaldo, R B Heberman, P Katz, A S Fauci.   

Abstract

Immunodeficiency disorders have provided much information on the development and interaction of the various B and T lymphoid components in the immune system of man. As the lymphoid system becomes increasingly divided into functional subsets of cells it will be important to find immunodeficiencies affecting newly discovered cell types. Natural killer (NK) cells are a recently described but ill-defined subpopulation of lymphocytes which is thought to play an important part in surveillance against tumour development. Mice homozygous for the beige gene were found to have a selective deficiency in NK function and were more susceptible to transplantation of syngeneic tumours as predicted. We report here that patients carrying the analogous, autosomal recessive Chediak-Higashi (CH) gene have a profound defect in their ability to spontaneously lyse various tumour cells in vitro by either antibody-dependent or independent mechanisms. Since other cell-mediated cytolytic functions were relatively normal, these results suggest that the beige or Chediak-Higashi gene in both man and mouse controls NK function.

Entities:  

Mesh:

Year:  1980        PMID: 6445041     DOI: 10.1038/284553a0

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  64 in total

1.  Disparate effect of beige mutation on cytotoxic function between natural killer and natural killer T cells.

Authors:  M Bannai; H Oya; T Kawamura; T Naito; T Shimizu; H Kawamura; C Miyaji; H Watanabe; K Hatakeyama; T Abo
Journal:  Immunology       Date:  2000-06       Impact factor: 7.397

2.  Cell-based flow cytometry assay to measure cytotoxic activity.

Authors:  Alessandra Noto; Pearline Ngauv; Lydie Trautmann
Journal:  J Vis Exp       Date:  2013-12-17       Impact factor: 1.355

3.  Cytolytic mechanisms involved in non-MHC-restricted cytotoxicity in Chediak-Higashi syndrome.

Authors:  T Nakazawa; K Agematsu; K Yasui; T Onodera; R Inoue; H Kaneko; N Kondo; M Yamamoto; N Kayagaki; H Yagita; K Okumura; A Komiyama
Journal:  Clin Exp Immunol       Date:  1999-10       Impact factor: 4.330

4.  Natural killer cell activity in asthma.

Authors:  T Timonen; B Stenius-Aarniala
Journal:  Clin Exp Immunol       Date:  1985-01       Impact factor: 4.330

5.  Epstein-Barr serology in immunodeficiencies: an attempt to correlate with immune abnormalities in Wiskott-Aldrich and Chediak-Higashi syndromes and ataxia telangiectasia.

Authors:  E Vilmer; G M Lenoir; J L Virelizier; C Griscelli
Journal:  Clin Exp Immunol       Date:  1984-02       Impact factor: 4.330

6.  Bone marrow transplantation (BMT) for the syndrome of pigmentary dilution and lymphohistiocytosis (Griscelli's syndrome).

Authors:  L C Schneider; R S Berman; C R Shea; A R Perez-Atayde; H Weinstein; R S Geha
Journal:  J Clin Immunol       Date:  1990-05       Impact factor: 8.317

7.  Depressed levels of granular lymphocytes with natural killer (NK) cell function in 247 cancer patients.

Authors:  C M Balch; A B Tilden; P A Dougherty; G A Cloud
Journal:  Ann Surg       Date:  1983-08       Impact factor: 12.969

8.  Natural killer cell in systemic lupus erythematosus. Defects in effector lytic activity and response to interferon and interferon inducers.

Authors:  W L Sibbitt; P M Mathews; A D Bankhurst
Journal:  J Clin Invest       Date:  1983-05       Impact factor: 14.808

9.  Natural cell-mediated cytotoxicity in normal human peripheral blood lymphocytes and its in vitro boosting with BCG.

Authors:  R Mandeville; F M Sombo; N Rocheleau
Journal:  Cancer Immunol Immunother       Date:  1983       Impact factor: 6.968

10.  Natural killer activity of peripheral blood lymphocytes and its relation to histopathological factors of lung cancer.

Authors:  A Terazawa; N Tanaka; N Senou; F Inoue; H Matsuura; A Gouchi; S Fuchimoto; H Mimura; K Orita
Journal:  Jpn J Surg       Date:  1987-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.